Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

Inclusion Criteria: * 1\. Age 18-75 years old, male or female; * 2\. ECOG 0-3, for patients with ECOG=4, if ECOG reach 0-3 after bridging treatment with ibrutinib, they are also considered to fit this criteria; * 3\. Histologically diagnosed as B cell non-Hodgkin's lymphoma (NHL)(according to WHO 2008 criteria), including DLBCL-NOS, primary mediastinal B cell lymphoma (PMBCL) mantel cell lymphoma (MCL), transformed follicular lymphoma (TFL) and other transformed B cell NHL; * 4\. CD19 positive (by immuno-histology or flowcytometry) \[for DLBCL/PMBCL/TFL patients, negative CD19 immuno-histology results also acceptable\]; * 5\. Definition of relapsed and refractory disease: 1) refractory DLBCL should fit one of the following: ①complete remission NOT achieved after 2nd line treatment; ②progression of disease during treatment; ③duration of stable disease \<6 months; ④ disease progress or relapse within 12 months of autologous stem cell transplantation. 2\) definition of refractory/relapsed disease for CLL and other indolent B cell NHL, should fit one of the following: ① failed or relapsed after 2nd therapy (Rituximab must be included) and being unable to accept ibrutinib treatment due to various reasons; ② non-responsive or intolerable to ibrutinib as 2nd line treatment; 3) refractory or relapsed MCL should fit one of the following: ① complete remission not achieved after 2nd line treatment; ② disease progression during treatment; ③duration of stable disease ≤6 months; ④disease progress or relapse within 12 months of autologous stem cell transplantation. * 6\. Previous treatment of aggressive B lymphomas must include Rituximab and anthracyclines; * 7\. Patients should have at least one measurable disease focus, with the longitudinal diameter ≥1.5cm, or any extra-nodal focus with the longitudinal diameter ≥1.0cm, with PET/CT positive results; * 8\. Blood routine test, absolute neutrophil count≥1000/ul、platelet count≥45000/ul； * 9\. Cardiac, hepatic and renal function: Creatinin \<1.5 times of normal maximum；ALT/AST level \<2.5 times of the maximum of normal range; total bilirubin\<1.5 times of ULN；cardiac ejection fraction≥ 50%; * 10\. Patients should have the ability to fully understand contents of the written consent and be willing to sign the written consent; * 11\. Fertile patients should agree to take contraceptive measures during the process of this trial. Exclusion Criteria: * 1\. History of other malignant tumor; * 2\. History of autologous stem cell transplantation within 6 weeks prior to enrollment; * 3\. Received CAR-T therapy within 3 months prior to enrollment; * 4\. Received cytotoxic medicine or glucocorticoids or other targeted-therapy medicine (except for ibrutinib) within 2 weeks prior to T cell collection; * 5\. With active autoimmune disease; * 6\. With active infection; * 7\. With HIV infection, or uncontrolled HBV/HCV/syphilis infection; * 8\. With known central nervous system lymphoma.